



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: August 15, 2008

To: Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist

Re: N0626, Phase II Randomized Study Pemetrexed With Sorafenib versus Pemetrexed
Alone as Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Due to the inclusion of central review of tissue to confirm diagnosis, please submit tissue for central review for all patients (including those enrolled prior to Addendum 4).

If you have any questions, please feel free to contact me at 507/538-3893.